锝-99m苯并咪唑基亚氨基二乙酸肝胆放射性药物：结构与生物分布研究

Technetium-99m benzimidazolyl iminodiacetic acid hepatobiliary radiopharmaceuticals: structure biodistribution studies.

作者信息

Hunt F C, Maddalena D J, Wilson J G

出版信息

Int J Nucl Med Biol. 1984;11(3-4):219-23. doi: 10.1016/0047-0740(84)90003-2.

Abstract

The biodistribution of fifteen structural variants of the hepatobiliary radiopharmaceutical, technetium-99m benzimidazolyl iminodiacetic acid (BIMIDA) were determined 1 h after i.v. injection into rats. The best compounds with respect to hepatobiliary excretion were those with halogen substituents in the benzene ring of the BIMIDA ligand. The cholescintigraphic properties of the BIMIDA compounds compared favourably with those of technetium-99m acetanilido iminodiacetic acid (HIDA) radiopharmaceuticals.

摘要

在给大鼠静脉注射后1小时，测定了肝胆放射性药物锝-99m苯并咪唑基亚氨基二乙酸（BIMIDA）的15种结构变体的生物分布。就肝胆排泄而言，最佳化合物是BIMIDA配体苯环上带有卤素取代基的那些化合物。BIMIDA化合物的胆管闪烁造影特性与锝-99m乙酰苯胺基亚氨基二乙酸（HIDA）放射性药物相比具有优势。